



Argos Therapeutics
Investor Relations Department
4233 Technology Drive
Durham, NC 27704
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARG5


Last Trade:	1.10
Trade Time:	3:59 PM ET Apr 18, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.70 - 12.00
Volume	676,937

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Apr 19, 2018*
[Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives](#)
- Apr 2, 2018*
[Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights](#)
- Mar 28, 2018*
[Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018](#)
- Feb 15, 2018*
[Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy](#)
- Feb 5, 2018*
[Argos Obtains Option to License PD1 Checkpoint Inhibitors](#)

Financials [\[View all \]](#)

- Apr 2, 2018*
[Annual Report \(10-K\)](#)
- Jul 6, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)